196 results
Page 2 of 10
8-K
EX-10.3
64jmukued gug20osd3
8 Nov 22
Hepion Pharmaceuticals Announces Pricing of $20.0 Million Private Placement of Convertible Redeemable Preferred Stock
8:41pm
8-K
EX-3.1
ra2v27iyhdc lzc2h80
8 Nov 22
Hepion Pharmaceuticals Announces Pricing of $20.0 Million Private Placement of Convertible Redeemable Preferred Stock
8:41pm
DEFA14A
8uf f76uggx
22 Jul 22
Additional proxy soliciting materials
9:31pm
8-K
EX-99.1
meg9v 0rib87shp
28 Jun 22
Departure of Directors or Certain Officers
9:46am
DEFA14A
sdmnws5v92ha5xm y2eu
24 Jun 22
Additional proxy soliciting materials
4:24pm
DEFA14A
sbnaw17m
31 May 22
Additional proxy soliciting materials
4:52pm
8-K
EX-99.2
tue48
27 May 22
Regulation FD Disclosure
8:44am
8-K
EX-99.1
y7m49fu0 7y5l1dg6t
6 Jan 22
Hepion Pharmaceuticals Announces USAN Selection of “Rencofilstat” as Nonproprietary Name for CRV431
5:18pm
8-K
EX-99
r0g8flwev2kh
21 Dec 21
Hepion Pharmaceuticals Announces FDA Clearance of IND Application for CRV431 in the Treatment of Liver Cancer
8:25am
8-K
EX-99.1
77rkqhq3ncd
30 Nov 21
Hepion Pharmaceuticals Receives FDA Fast Track Designation for CRV431 for the Treatment of NASH
8:10am
8-K
EX-99.1
sfwb3mncynikizu92q
16 Nov 21
Hepion Pharmaceuticals and FibroFind Announce Anti-Cancer Activity of CRV431 in a Nonclinical Liver Cancer Study
8:53am
8-K
EX-99.2
c6x8jnr14obh5633eiy
10 Nov 21
Hepion Pharmaceuticals Announces Poster Details for the Upcoming AASLD The Liver Meeting® 2021
9:41am
8-K
EX-99.1
5608c3o
10 Nov 21
Hepion Pharmaceuticals Announces Poster Details for the Upcoming AASLD The Liver Meeting® 2021
9:41am
8-K
EX-99.1
8wahtq2n6doxpokh5ov
7 Oct 21
Hepion Pharmaceuticals to Participate in the H.C. Wainwright 5th Annual NASH Investor Conference
4:24pm
8-K
EX-99.1
mmylw
29 Sep 21
Other Events
9:22am
8-K
EX-99.1
1vc0hep wy3s
13 Sep 21
Regulation FD Disclosure
8:28am